AgeneBio is a brand dedicated to developing innovative therapeutics for patients suffering from neurological and psychiatric diseases. Their mission is to preserve and restore brain function for individuals at risk of neurodegeneration, aiming to improve lives and benefit society as a whole. With a focus on cognitive neuroscience and the aging brain, AgeneBio's pipeline includes multiple novel therapies being evaluated for neurological and psychiatric conditions.

Their most advanced clinical program is in late-stage development, targeting amnestic mild cognitive impairment due to Alzheimer's disease (MCI due to AD). Currently, there are no FDA-approved treatments for this condition, making AgeneBio's efforts crucial. Their lead asset, AGB101, is undergoing Phase 2b trials following an FDA-agreed protocol.

Additionally, AgeneBio's innovative discovery program is exploring the potential of GABA(A) α5 positive allosteric modulators for a range of conditions, including MCI due to AD and schizophrenia. However, please note that these investigational compounds are not yet approved by the FDA, and their safety and efficacy have not been established. AgeneBio's dedication to research and development is driven by their aim to revolutionize the field of brain function preservation and improve the lives of patients facing these challenging conditions